Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|ARAR0331||COG||Treatment of Childhood Nasopharyngeal Carcinoma with Neoadjuvant Chemotherapy and Concomitant Chemoradiotherapy: A Groupwide Phase III Study||Pediatric CIRB||Available to Open|
|ACNS0333||COG||Treatment of Atypical Teratoid/Rhabdoid Tumors (AT/RT) of the Central Nervous System with Surgery; Intensive Chemotherapy; and 3-D Conformal Radiation: A Phase III Group-Wide Study||Pediatric CIRB||Available to Open|
|ARAR0332||COG||Treatment of Adrenocortical Tumors with Surgery plus Lymph Node Dissection and Multiagent Chemotherapy: A Groupwide Phase III Study||Pediatric CIRB||Available to Open|
|AREN0532||COG||Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor: A Groupwide Phase III Study||Pediatric CIRB||Available to Open|
|AREN0534||COG||Treatment for Patients with Bilateral; Multicentric; or Bilaterally-Predisposed Unilateral Wilms Tumor: A Groupwide Phase III Study||Pediatric CIRB||Available to Open|
|EA1151||ECOG-ACRIN||Tomosynthesis Mammographic Imaging Screening Trial (TMIST)||Cancer Prevention and Control CIRB||Available to Open|
|TRC-10446||NCI||Tocilizumab in Hospitalized Cancer Patients with Coronavirus 2019 (SARS-CoV-2) and Severe Complications of Coronavirus Disease 19 (COVID-19)||Adult CIRB - Late Phase Emphasis||Available to Open|
|AAML0431||COG||The Treatment of Down Syndrome Children with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Under the Age of 4 Years: A Groupwide Phase III Study||Pediatric CIRB||Available to Open|
|APEC14B1||COG||The Project: Everychild Protocol: A Registry; Eligibility Screening; Biology and Outcome Study||Pediatric CIRB||Available to Open|
|10264||ETCTN||The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. A Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome||Adult CIRB - Early Phase Emphasis||Available to Open|